|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
1P20CA192976-01
|
$144,556
|
$67,941
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
Core Support for Cancer Center
|
3P30CA013330-41S1
|
$75,000
|
$1,500
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
3P30CA013330-41S2
|
$148,500
|
$2,970
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
5P30CA013330-41
|
$3,585,248
|
$71,705
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Genomics and Predictive Modeling of Prostate Cancer Heath Disparity
|
5U01CA158431-04
|
$311,028
|
$311,028
|
OSTRER, HARRY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The B7x pathway in the tumor microenvironment
|
1R01CA175495-01A1
|
$346,525
|
$86,631
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The B7x pathway in the tumor microenvironment
|
3R01CA175495-01A1S1
|
$59,075
|
$14,769
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Nemours Community Clinical Oncology Program
|
3U10CA176879-01S1
|
$89,460
|
$8,946
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
A Potent Small Molecule Chemokine Antagonist Blocks Tumor Cell Dissemination In V
|
1R43CA183362-01A1
|
$224,748
|
$112,374
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
RTOG Biospecimen Repository
|
3U24CA114734-08S1
|
$946,151
|
$94,615
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
2014 AUA Urological Oncology Research Symposium: ""Progress in Translational Uro
|
1R13CA186649-01
|
$6,000
|
$2,040
|
GIAMBARRESI, LEO
|
AMERICAN UROLOGICAL ASSOCIATION
|
|
Bay Area Tumor Institute CCOP
|
3U10CA045461-24S1
|
$81,028
|
$8,913
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Maf1, a novel negative transcriptional regulator of the TATA binding protein
|
7R01CA074138-16
|
$244,696
|
$244,696
|
JOHNSON, DEBORAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S1
|
$75,000
|
$2,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S3
|
$48,834
|
$1,465
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S4
|
$149,801
|
$4,494
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-08
|
$2,746,741
|
$82,402
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
METABOLOMIC PROFILING AND BIOLOGIC BASIS OF RACIAL DISPARITY IN PROSTATE CANCER
|
3U01CA167234-03S1
|
$100,437
|
$100,437
|
SREEKUMAR, ARUN
|
BAYLOR COLLEGE OF MEDICINE
|
|
METABOLOMIC PROFILING AND BIOLOGIC BASIS OF RACIAL DISPARITY IN PROSTATE CANCER
|
5U01CA167234-03
|
$314,393
|
$314,393
|
SREEKUMAR, ARUN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-29S1
|
$86,403
|
$10,368
|
NICHOLS, CRAIG
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
SOX9 Mediation of AR and ERG Driven Prostate Cancer
|
1R01CA168393-01A1
|
$361,050
|
$361,050
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Androgen Receptor Action in Castration Resistant Prostate Cancer
|
5P01CA163227-02
|
$2,010,837
|
$2,010,837
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Akt isoform-specific signaling in breast cancer metastasis
|
4R00CA157945-03
|
$224,100
|
$56,025
|
CHIN, YUET MING REBECCA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Elucidating a Novel Akt Activation Mechanism for Targeted Prostate Cancer Therapy
|
1K99CA181342-01A1
|
$169,668
|
$169,668
|
LIU, PENGDA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
PTEN in ontogenesis and tumor suppression
|
5R01CA082328-17
|
$326,142
|
$81,536
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of POZ-zinc finger proteins in tumorigenesis.
|
5R01CA102142-10
|
$321,009
|
$105,933
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A metabolic role for PML in tumor suppression
|
5R01CA142780-05
|
$339,713
|
$84,928
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Controlling cancer with aspirin-triggered stimulation of resolution
|
5R01CA170549-03
|
$490,642
|
$161,912
|
PANIGRAHY, DIPAK
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Heme degradation pathway and immunomodulation in prostate cancer.
|
5R21CA169904-02
|
$183,549
|
$183,549
|
WEGIEL, BARBARA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQC3) Using an Immunoscore to Assess Tumor-medicated Immune Variations in Africa
|
1R21CA190076-01
|
$127,238
|
$127,238
|
WALLACE, TIMOTHY
|
BON SECOURS RICHMOND COMMUNITY HOSPITAL
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S5
|
$110,177
|
$18,730
|
KACHNIC, LISA
|
BOSTON MEDICAL CENTER
|
|
Combination Therapies for Cancer Treatment
|
5R01CA049248-24
|
$318,393
|
$108,254
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Angiogenin-induced RNA cleavage in cancer
|
5R01CA168872-02
|
$346,327
|
$173,164
|
ANDERSON, PAUL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Hypogonadism and Pain Perception in Androgen-Deprived Men with Prostate Cancer
|
5R21CA171316-02
|
$191,059
|
$191,059
|
BASARIA, SHEHZAD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
1U10CA180821-01
|
$10,540,919
|
$632,455
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S1
|
$228,063
|
$13,684
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S2
|
$264,661
|
$15,880
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S3
|
$16,838
|
$1,010
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Quantitiative MRI of prostate cancer as a biomarker and guide for treatment
|
5U01CA151261-05
|
$309,543
|
$309,543
|
FENNESSY, FIONA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Quantitative Image Informatics for Cancer Research (QIICR)
|
5U24CA180918-02
|
$647,864
|
$220,274
|
KIKINIS, RON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Advancement and Validation of Prostate Diffusion and Spectroscopic MRI
|
5R01CA160902-03
|
$421,068
|
$421,068
|
MAIER, STEPHAN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
VITamin D and omegA-3 triaL (VITAL)
|
5U01CA138962-06
|
$1,849,394
|
$369,879
|
MANSON, JOANN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
|
5R00CA160350-04
|
$241,349
|
$120,675
|
SHI, JINJUN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Endothelin Mechanisms in Metastic Prostate Cancer Pain
|
5R01CA080153-14
|
$403,886
|
$403,886
|
STRICHARTZ, GARY
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Enabling Technologies for MRI-Guided Prostate Interventions
|
5R01CA111288-09
|
$555,472
|
$555,472
|
TEMPANY, CLARE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Novel compounds that inhibit transactivation of N-terminal domain of the androgen
|
5R01CA105304-10
|
$265,355
|
$265,355
|
SADAR, MARIANNE
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Broad Institute Center for Cancer Systems Biology
|
5U54CA112962-10
|
$2,106,778
|
$526,695
|
GOLUB, TODD
|
BROAD INSTITUTE, INC.
|
|
DEVELOPMENT OF THE EDRN INFORMATICS CENTER IN SUPPORT OF BIOMARKER RESEARCH AND V
|
ACN12001001
|
$1,299,221
|
$1,299,221
|
UNKNOWN, UNKNOWN
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Obesogenic environment: impact on breast, colorectal, and prostate cancer risk
|
5R01CA154644-05
|
$334,144
|
$110,268
|
CHENG, IONA
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
|
Mitochondrial Genetic Susceptibility to Breast and Prostate Cancers
|
5R03CA173782-02
|
$72,265
|
$36,133
|
CHENG, IONA
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
Total relevant funding to Prostate for this search: $217,811,379
|